Antisoma goes back to basics following Phase III failure
This article was originally published in Scrip
Executive Summary
Antisoma is stopping all clinical development activity and is severely downsizing operations following the failure in Phase III of its lead programme, AS1413, a topoisomerase II inhibitor, in secondary acute myeloid leukaemia (AML). The trial failed to meet the primary endpoint and development of AS1413 will be discontinued.